RET and neuroblastoma: Regorafenib treatment of neuroblastoma cells resulted in reduced phosphorylation of RET within 4 h of regorafenib exposure in a dose-dependent manner (Fig. 3a), with reduced total RET levels also observed in SK-N-SH and SK-N-BE(2) cells after 24 h of exposure (Fig. 3a, b).